An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
|Videos|December 9, 2022
Dr. Antonarakis on available prostate cancer treatments driven by genetic testing
Author(s)Urology Times staff
Advertisement
Emmanuel S. Antonarakis, MD, discusses FDA-approved treatments currently available for prostate cancer that are selected based on genetic testing of patients. Antonarakis is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation
Advertisement
Related to this article
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
2
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
3
Matching mCSPC treatment to the patient, not just the trial data
4
Urocross Expander System enters US commercial use for symptomatic BPH
5